

III. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
森下英理子	循環抗凝固因子による出血傾向 後天性血友病A	畠清彦	血液症候群(第3版)-その他の血液疾患を含めて-	日本臨床	東京	2023	253-257
森下英理子	循環抗凝固因子による出血傾向 後天性第V因子欠乏症(第V因子インヒビター)	畠清彦	血液症候群(第3版)-その他の血液疾患を含めて-	日本臨床	東京	2023	258-262
森下英理子	後天性凝固線溶異常症 循環抗凝固因子による出血傾向 自己免疫性後天性第XIII因子欠乏症	畠清彦	血液症候群(第3版)-その他の血液疾患を含めて-	日本臨床	東京	2023	263-268
山之内純	特発性血小板減少性紫斑病	福井次矢, 高木誠, 小室一成, 阿部理一郎	今日の治療指針 2024	医学書院	東京	2024	701-703
加藤規利	血栓性微小血管症	南学正臣	腎臓内科レジデントマニュアル 改訂第9版	診断と治療社	日本	2023	
加藤規利	血栓性微小血管症(溶血性尿毒症症候群、血栓性血小板減少性紫斑病など)	福井次矢	今日の治療指針 2024年版 - 私はこう治療している	医学書院	日本	2024	627-628
立俵良崇、加藤規利、丸山彰一	TMA：分類を整理し、最新の治療に繋げる	南学正臣	腎臓内科診療の掟	中外医学社	日本	2023	203-212
加藤規利、丸山彰一	【出血傾向をきたす血小板減少症】非典型溶血性尿毒症症候群(aHUS) - 疾患概要と抗補体治療時代の治療戦略	森下英理子	医学のあゆみ	医歯薬出版株式会社	日本	2024	656-660
根木玲子、宮田敏行	【血栓に強くなる-産婦人科診療に活かす最新知識-】診断・治療 遺伝性・後天性血栓性素因と産科診療		産科と婦人科	(株)診断と治療社	東京	2023	1091-1097

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kobayashi T, Sugiura K, Ojima T, Serizawa M, Hirai K, Morishita E.	Thrombosis-related characteristics of pregnant women with antithrombin deficiency, protein C deficiency and protein S deficiency in Japan.	Thromb J	8;22(1)	18	2024
Sugihara H, Marumo A, Okabe H, Kohama K, Mera T, Morishita E.	Platelet and large platelet ratios are useful in predicting severity of COVID-19.	Int J Hematol		https://doi.org/10.1007/s12185-024-03737-9	2024
Togashi T, Nagaya S, Meguro-Horike M, Matsumoto H, Imai Y, Yamaguchi K, Fujii Y, Moriyama H, Kikuchi Y, Yasuda I, Horike SI, Morishita E.	Identification of two de novo variants causing inherited antithrombin deficiency by quantitative analysis of variant alleles.	Thromb Res	233	37-40.	2024
Imai Y, Nagaya S, Arai Y, Meguro-Horike M, Togashi T, Horike S, Kawasaki H, Morishita E.	Functional analysis of two abnormal antithrombin proteins with different intracellular kinetics.	Thromb Res	230	18-26	2023
Nagaya S, Togashi T, Akiyama M, Imai Y, Matsumoto H, Moriyama H, Meguro-Horike M, Yasuda I, Kikuchi Y, Kuwajima Y, Horike SI, Watanabe A, Morishita E.	Protein S deficiency caused by cryptic splicing due to the novel intron variant c.346+5G>C in PROS1.	Thromb Res	24;229	26-30	2023
Nagao A, Tokugawa T, Matsuo Y, Shirayama R, Morishita E, Nozima M, Kinai E, Nishida Y, Fukutake K.	The length of the sanitary napkins can be used as a handier index than pictorial blood loss assessment chart to predict the heavy menstrual bleeding.	J Obstet Gynaecol Res	49(7)	1838-1845	2023
Imai Y, Nagaya S, Arai Y, Meguro-Horike M, Togashi T, Ohmori K, Makita Y, Sato E, Yujiri T, Nagamori Y, Horike SI, Watanabe A, Morishita E.	Identification and functional analysis of three novel genetic variants resulting in premature termination codons in three unrelated patients with hereditary antithrombin deficiency.	Int J Hematol	117(4)	523-529	2023
森下英理子	凝固阻止因子活性が偽高値となる場合？	レジデントノート	25(18)	3358-3360	2024
森下英理子	COVID-19関連血栓・塞栓症とlong COVID	日本臨床	82(2)	268-274	2024
森下英理子	血液凝固線溶系の変化は？なぜ血液凝固線溶系は変化するのか？	周産期医学	53(増)	13-17	2023

森下英理子	凝固線溶系の見方と妊娠による変動	産科と婦人科	90(10)	1079-1085	2023
森下英理子	血栓・止血の入り口 出血傾向の鑑別診断	内科	132(4)	718-724	2023
長屋聡美, 森下英理子	血栓・止血に関連する疾患 A. 血栓性疾患 先天性アンチトロンビン欠乏症, 先天性プロテインC欠乏症, 先天性プロテインS欠乏症	内科	132(4)	725-730	2023
長屋聡美, 森下英理子	ワクチン起因性免疫性血栓性血小板減少症 (VITT) の病態と症状	Thromb Med	13(3)	149-154	2023
森下英理子	遺伝性血栓症の病態解析 Bedside to Bench	日本血栓止血学会誌	34(4)	468-479	2023
森下英理子	凝固系の副作用とくすり どうする?薬物治療中に現れる血栓症	薬局	74(8)	1459-1463	2023
森下英理子	実地医家が押さえておくべき診療のポイント 血栓性疾患の身体所見と臨床検査の進め方	Medical Practice	40(6)	846-853	2023
Kashiwagi H, Kuwana M, Murata M, Shimada, N, Takafuta T, Yamanouchi J, Kato H, Hato T, Tomiyama Y.	Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition	Int. J. Hematol	119(1)	1-13	2024
柏木浩和、桑名正隆、村田満、島田直毅、高蓋寿朗、山之内純、加藤恒、羽藤高明、富山佳昭	成人免疫性血小板減少症 診断参照ガイド2023年版	臨床血液	64(10)	397-405 1245-1257	2023
Uwamino Y, Nagashima K, Yoshifuji A, Suga S, Nagao M, Fujisawa T, Ryuzaki M, Takemoto Y, Namkoong H, Wakui M, Matsushita H, Hasegawa N, Sato Y, Murata M.	Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination	NPJ Vaccines	8(1):33.	doi: 10.1038/s41541-023-00626-w	2023
Takeuchi T, Tanaka S, Murata M, Tanaka Y.	Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial	Ann Rheum Dis	82(8)	1025-1034	2023

Uwamino Y, Yokoyama T, Sato Y, Shibata A, Kumrafuji T, Tanabe A, Noguchi M, Arai T, Ohno A, Yokota H, Namkoong H, Nishimura T, Kosaki K, Hasegawa N, Wakui M, Murata M, Matsushita H.	Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine	Vaccine	41(9)	1545-1549.	2023
Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, Kurahashi S, Kagoo T, Tanimoto K, Saotome S, and Tomiyama Y	Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: an open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study	Am. J. Hematol	99(2)	E55-E59	2024
Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, Kurahashi S, Kagoo T, Tanimoto K, Saotome S, Tomiyama Y, and R788-1301 Investigators	Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study	Br. J. Haematol.	200(6)	802-811	2023
山之内純	免疫性血小板減少症	Medical Practice	40(6)	874-877	2023
山之内純	免疫性血小板減少症の診断と治療	日本医師会雑誌	152(12)	1353-1356	2024
Sakai K, Miyadera H, Kubo M, Nakajima F, Matsumoto M.	Overlapping ADAMTS13 peptide binding profiles of DRB1*08:03 and DRB1*11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura.	J Thromb Haemost	21	616-628	2023
Yamada S, Asakura H, Kubo M, Sakai K, Miyamoto T, Matsumoto M.	Distinguishing immune-mediated thrombotic thrombocytopenic purpura from septic disseminated intravascular coagulation using plasma levels of haptoglobin and factor XIII activity.	Res Pract Thromb Hae.	7	100076	2023
Miyakawa Y, Imada K, Ichikawa S, Uchiyama H, Ueda Y, Yonezawa A, Fujitani S, Ogawa Y, Matsushita T, Asakura H, Nishio K, Suzuki K, Hashimoto Y, Murakami H, Tahara S, Tanaka T, Matsumoto M.	The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.	Int J Hematol.	117	366-377	2023

Wada H, Teranishi H, Shimono A, Kato N, Maruyama S, Matsumoto M.	Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab.	Thromb J	21	43	2023
Nishimura N, Yoshimoto K, Yada N, Kakiwaki A, Sawa A, Senzaki S, Kawashima H, Yoneima R, Ono S, Sakai K, Matsumoto M, Fukushima H, Nishio K.	The combination of the Lactate dehydrogenase/hemoglobin ratio with the PLASMIC score facilitates differentiation of TTP from septic DIC.	Clin Appl Thromb Hemost.	29	1-8	2023
Sakai K, Matsumoto M, De Waele L, Dekimpe C, Hamada E, Kubo M, Tersteeg C, De Meyer SF, Vanhoorelbeke K.	ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura.	Blood Adv	7	131-140	2023
Saito K, Sakai K, Kubo M, Azumi H, Hamamura A, Ochi S, Amagase H, Kunieda H, Ogawa Y, Yagi H, Matsumoto M.	Persistent ADAMTS13 Inhibitor Delays Recovery of ADAMTS13 activity in Caplacizumab-Treated Japanese iTTP Patients.	Blood Adv	In press		2024
Kubo M, Matsumoto M.	Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura.	Int J Hematol	117	331-340	2023
Sakai K, Matsumoto M.	Clinical Manifestations, Current and Future Therapy, and Long-Term Outcomes in Congenital Thrombotic Thrombocytopenic Purpura.	J Clin Med.	12		2023
Matsumoto M, Miyakawa Y, Kokame K, Ueda Y, Wada H, Higasa S, Yagi H, Ogawa Y, Sakai K, Miyata T, Morishita E, Fujimura Y; For TTP group of Blood Coagulation Abnormalities Research Study Team, Research on Rare and Intractable diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan.	Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023	Int J Hematol	118	529-546	2023

Osawa K (Kato.N, Maruyama.S)	Overlapping Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy with Mutation in CFI in a Japanese Patient: A Case Report.	Internal Medicine	6	2713-23	2023
Tasaki.Y (Kato.N, Maruyama.S)	Case report: A family of atypical hemolytic uremic syndrome involving a CFH::CFHR1 fusion gene and CFHR3-1-4-2 gene duplication.	Frontiers in Immunology		1360855	2024
Roth A, et al	Long term sutimlimab improves quality of life for patients with cold agglutinin disease	Blood Adv	7	5890-5897	2023
Roth A, et al.	Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease	Am J Hematol	98	1246-1253	2023
Miyakawa Y, et al	The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study	Int J Hematol	117	366-377	2023
Shindo R, et al	Involvement of the complement system in immune thrombocytopenia: review of the literature	Immunol Med	46	182-190	2023
Broome CM, et al	Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial	Lancet	402	1648-1659	2023

Okubo N, Sugawara S, Fujiwara T, Sakatsume K, Doman T, Yamashita M, Goto K, Tateishi M, Suzuki M, Shirakawa R, Eura Y, Kokame K, Hayakawa M, Matsumoto M, Kawate Y, Miura M, Takiguchi H, Soga Y, Shirai S, Ando K, Arai Y, Nakayoshi T, Fukumoto Y, Takahama H, Yasuda S, Tamura T, Watanaabe S, Kimura T, Yaoita N, Shimokawa H, Saiki Y, Kaikita K, Tsujita K, Yoshii S, Nakase H, Fujimaki SI, Horiuchi H	von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis	Res Pract Thromb Haemost	8(1)	102284	2023
Fukuma K, Yamagami H, Ihara M, Tanaka T, Miyata T, Miyata S, Kokame K, Nishimura K, Nakamoto Y, Yamamoto H, Hayakawa M, Kamiyama K, Etomoto Y, Itabashi R, Furui E, Manabe Y, Ezura M, Todo K, Hashikawa K, Uchiyama S, Toyoda K, Nagatsuka K	P2Y12 reaction units and clinical outcomes in acute large artery atherosclerotic stroke: a multicenter prospective study	J Atheroscler Thromb	30(1)	39-55	2023
Tsuji A, Miyata T, Sekine A, Neki R, Kokame K, Tomita T, Kashima Y, Asano R, Ueda J, Aoki T, Ogo T	Three cases of unprovoked venous thromboembolism with prothrombinop.Arg596Gln variant and literature review of antithrombin resistance	Intern Med	62(6)	885-888	2023
秋山正志, 小亀浩市	von Willebrand因子・ADAMTS13研究における最近の進歩	Thromb Med	In press		2024
Shirozu H, Ichiyama M, Ishimura M, Kuraoka A, Egami N, Dongchon K, Ohga S, Nakano T, Sagawa K.	Thrombosed pulmonary artery and ductus arteriosus aneurysm in a heritable protein S-deficient newborn	AJP Rep	13(3)	e44-e48	2023
Tanaka A, Sakaguchi Y, Inoue H, Egami N, Sonoda Y, Sonoda M, Ishimura M, Ochiai M, Hotta T, Uchiumi T, Sakai Y, Ohga S.	Stroke in a protein C-deficient infant after stem cell transplant for CHARGE syndrome.	Pediatr Blood Cancer	70(4)	e30047	2023
石村匡崇	血液学的検査 プロテインC, プロテインS	小児臨床検査ガイド	第3版	98-100	2023
江上直樹, 落合正行, 市山正子, 井上普介, 園田素史, 石村匡崇, 堀田多恵子, 内海健, 康東天, 大賀正一	血栓性素因スクリーニングの臨床的意義 新生児血栓症の全国調査からの洞察	日本産婦人科・新生児血液学会誌	32(2)	51-58	2023

落合正行、大賀正一	新生児溶血性貧血	日本臨牀 血液症候群(第3版) I	26	372-375	2023
江上直樹、落合正行、石村匡崇、大賀正一	【匠から学ぶ 血栓止血検査ガイド】(5章) 疾患まとめ 小児領域のDIC	検査と技術	51(9)	1101-1105	2023
松下 正	先天性・後天性血友病診療の最前線	日本内科学会雑誌	112(12)	2287-2294	2023
TsujiA, MiyataT, SekineA, NekiR, KokameK, TomitaT, Kashima Y, Asano R, UedaJ, AokiT, OgoT	Three Cases of Unprovoked Venous Thromboembolism with Prothrombin p.Arg596Gln Variant and a Literature Review of Antithrombin Resistance	Internal Medicine	62	885-888	2023
根木玲子	新生児から成人期までに発症する特発性血栓症の診療ガイド	診断と治療社	In press		2024